“Curcumin for monoclonal gammopathies. What can we hope for, what should we fear.” My comments on the Vermorken study, 2012. Part II.

I thought the business of dividing this post into different “chapters” might end up being confusing. So before I launch into today’s bunch of chapters, I just wanted to point out that I did this in order to make reading them a bit easier on the eyes, that’s all.  CHAPTER THREE. Now we’ve reached paragraph […]